. Author manuscript; available in PMC: 2016 Apr 14.

Published in final edited form as: Am J Obstet Gynecol. 2014 Apr 23;211(5):512.e1–512.e6. doi: 10.1016/j.ajog.2014.04.027

TABLE 2.

Comparisons of baseline values of serum biomarkers for the whole cohort based on preeclampsia status

Serum biomarker^a	Preeclampsia n = 263^c	No preeclampsia n = 995^c	P value^b
Angiogenin, pg/mL	265 (253.3–276.9)	240 (234.3–246.6)	<.001
hCG, IU/mL^d	23,952 (20,993–27,328)	18,141 (17,052–19,299)	<.001
Progesterone, ng/mL^d	48.92 (45.41–52.71)	44.65 (43.12–46.24)	.03
sTNFr-2, pg/mL	2707 (2595–2823)	2572 (2517–2629)	.035
TNF-α, pg/mL	3.03 (2.87–3.19)	2.74 (2.60–2.89)	.008
(sFlt-1+endoglin)/PlGF	42.95 (33.25–55.47)	32.50 (28.49–37.08)	.06

BMI, body mass index; CI, confidence interval; hCG, human chorionic gonadotropin; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase; sTNFr-2, soluble tumor necrosis factor receptor 2; TNF-α, tumor necrosis factor-alpha.

All reported means are geometric means with 95% CI with the exception of angiogenin, which is reported as arithmetic means with 95% CI;

Comparisons between groups were made using a regression model adjusting for gestational age at the time the serum biomarker was drawn and prepregnancy maternal BMI;

Available sample size for each biomarker ranged as follows: angiogenin (214–790), hCG (108–491), progesterone (108–494), sTNFr-2 (214–790), TNF-α (261–59), (sFlt-1+endoglin)/PlGF (38–138) for preeclampsia and no preeclampsia groups, respectively;

Multiple gestation group excluded for this comparison.

Metz. Preeclampsia biomarkers in high-risk groups. Am J Obstet Gynecol 2014.